XenTech is a Patient-Derived Tumor Xenograft platform

Offering preclinical cancer models and services for translational drug development

To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.

Database access

Search your model into our PDX library

Login :

Password :

> Create an account

Latest news

February 8 – 9, 2016 | Berlin, Germany | World ADC

February 8th and 9th, 2016, Xentech will attend to the World ADC conferences in Berlin. The event highlights all aspect of Antibody Drug Conjugate drug development from discovery, preclinical, clinical and marketisation. Two members of our scientific team will attend to this 6th edition of Wordl ADC. Come to see us!

Company

Contract Research Organization

XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....

Partnerships

Research collaborations

XenTech has several research collaborations with pharmaceutical and biotechnology companies and with academic institutions. XenTech has established key collaborations with clinical centers in France...